Hasil Pencarian - Judith A Fox

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

    Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase oleh Burcu Aslan, Stefan Edward Hubner, Judith A. Fox, Pietro Taverna, William G. Wierda, Steven M. Kornblau, Varsha Gandhi

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

    Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. oleh Rachael E Hawtin, David E Stockett, Jo Ann W Byl, Robert S McDowell, Tan Nguyen, Michelle R Arkin, Andrew Conroy, Wenjin Yang, Neil Osheroff, Judith A Fox

    Diterbitkan 2010-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

    A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia oleh Jeffrey E. Lancet, Gail J. Roboz, Larry D. Cripe, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Tianling Chen, Rachael Hawtin, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, Judith E. Karp

    Diterbitkan 2015-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

    Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies oleh John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

    Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia oleh Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, Heinz-August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortes, Angelo-Michele Carella, Miklos Egyed, Utz Krug, Judith A. Fox, Adam R. Craig, Renee Ward, Jennifer A. Smith, Gary Acton, Hagop M. Kantarjian, Robert K. Stuart

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: